Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

MRI in breast cancer therapy monitoring.

McLaughlin R, Hylton N.

NMR Biomed. 2011 Jul;24(6):712-20. doi: 10.1002/nbm.1739. Epub 2011 Jun 21. Review.

2.

Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.

Hahn SY, Ko EY, Han BK, Shin JH, Ko ES.

Eur J Radiol. 2014 Feb;83(2):283-8. doi: 10.1016/j.ejrad.2013.10.023. Epub 2013 Nov 20.

PMID:
24315957
3.
4.

Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging.

Abraham DC, Jones RC, Jones SE, Cheek JH, Peters GN, Knox SM, Grant MD, Hampe DW, Savino DA, Harms SE.

Cancer. 1996 Jul 1;78(1):91-100.

5.

Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer.

Turnbull LW.

NMR Biomed. 2009 Jan;22(1):28-39. doi: 10.1002/nbm.1273. Review.

PMID:
18654999
6.

Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.

Cheung YC, Chen SC, Su MY, See LC, Hsueh S, Chang HK, Lin YC, Tsai CS.

Breast Cancer Res Treat. 2003 Mar;78(1):51-8.

PMID:
12611457
7.

Magnetic resonance imaging evaluation of residual tumors in breast cancer after neoadjuvant chemotherapy: surgical implications.

Zhou J, Li G, Sheng F, Qiao P, Zhang H, Xing X.

Acta Radiol. 2016 May;57(5):529-37. doi: 10.1177/0284185115597263. Epub 2015 Jul 31.

PMID:
26231950
8.

Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients.

Jensen LR, Garzon B, Heldahl MG, Bathen TF, Lundgren S, Gribbestad IS.

J Magn Reson Imaging. 2011 Nov;34(5):1099-109. doi: 10.1002/jmri.22726. Epub 2011 Aug 23.

PMID:
22002757
9.

MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy.

Belli P, Costantini M, Malaspina C, Magistrelli A, LaTorre G, Bonomo L.

Clin Radiol. 2006 Nov;61(11):946-53.

PMID:
17018307
10.

Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings.

Woodhams R, Kakita S, Hata H, Iwabuchi K, Kuranami M, Gautam S, Hatabu H, Kan S, Mountford C.

Radiology. 2010 Feb;254(2):357-66. doi: 10.1148/radiol.2542090405.

PMID:
20093508
11.

Magnetic resonance imaging: the evolution of breast imaging.

Heywang-Köbrunner SH, Hacker A, Sedlacek S.

Breast. 2013 Aug;22 Suppl 2:S77-82. doi: 10.1016/j.breast.2013.07.014. Review.

PMID:
24074797
12.

Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI.

Kim HJ, Im YH, Han BK, Choi N, Lee J, Kim JH, Choi YL, Ahn JS, Nam SJ, Park YS, Choe YH, Ko YH, Yang JH.

Acta Oncol. 2007;46(7):996-1003.

PMID:
17851879
13.

The application of breast MRI in staging and screening for breast cancer.

Gundry KR.

Oncology (Williston Park). 2005 Feb;19(2):159-69; discussion 170, 173-4, 177. Review.

14.

Utilisation of MR spectroscopy and diffusion weighted imaging in predicting and monitoring of breast cancer response to chemotherapy.

Leong KM, Lau P, Ramadan S.

J Med Imaging Radiat Oncol. 2015 Jun;59(3):268-77. doi: 10.1111/1754-9485.12310. Epub 2015 Apr 24. Review.

PMID:
25913106
15.

Clinical application of magnetic resonance imaging in management of breast cancer patients receiving neoadjuvant chemotherapy.

Chen JH, Su MY.

Biomed Res Int. 2013;2013:348167. doi: 10.1155/2013/348167. Epub 2013 Jun 5. Review.

16.

Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy.

Schott AF, Roubidoux MA, Helvie MA, Hayes DF, Kleer CG, Newman LA, Pierce LJ, Griffith KA, Murray S, Hunt KA, Paramagul C, Baker LH.

Breast Cancer Res Treat. 2005 Aug;92(3):231-8.

17.

Prediction of pathologic response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and MRS.

Shin HJ, Baek HM, Ahn JH, Baek S, Kim H, Cha JH, Kim HH.

NMR Biomed. 2012 Dec;25(12):1349-59. doi: 10.1002/nbm.2807. Epub 2012 May 6.

PMID:
22566277
18.

Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy.

Marinovich ML, Houssami N, Macaskill P, Sardanelli F, Irwig L, Mamounas EP, von Minckwitz G, Brennan ME, Ciatto S.

J Natl Cancer Inst. 2013 Mar 6;105(5):321-33. doi: 10.1093/jnci/djs528. Epub 2013 Jan 7. Review.

PMID:
23297042
19.

Diffusion-weighted magnetic resonance imaging of breast lesions: first experiences at 3 T.

Lo GG, Ai V, Chan JK, Li KW, Cheung PS, Wong TT, Ma M, Lee R, Chien D.

J Comput Assist Tomogr. 2009 Jan-Feb;33(1):63-9. doi: 10.1097/RCT.0b013e318165dc6b.

PMID:
19188787
20.

Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.

Li SP, Taylor NJ, Makris A, Ah-See ML, Beresford MJ, Stirling JJ, d'Arcy JA, Collins DJ, Padhani AR.

Radiology. 2010 Dec;257(3):643-52. doi: 10.1148/radiol.10100421. Epub 2010 Sep 21.

PMID:
20858850

Supplemental Content

Support Center